Zydus Lifesciences share news, announcements and annual reports
NSE: ZYDUSLIFEBSE: 532321Pharmaceuticals & BiotechnologyMid Cap
Zydus Lifesciences Limited · Formerly Cadila Healthcare · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2000
Last close ₹1,245.50up ₹61.10 (5.16%)BSE ₹1,244.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,184.40.
30 Oct: open ₹1,190.00, high ₹1,248.90, low ₹1,182.00
52-week range of traded prices to 30 Oct 2026
₹835.50Low, 2 Apr 2026₹1,248.90High, 30 Oct 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,24,239 Cr114th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 27.53
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 24.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.58
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 19.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 36,60,70935.2% delivered
Zydus Lifesciences share news and announcements
1,762 announcements, routine notices left out, newest first. Page 31 of 36.
May 2013
30 May · Dividend
Dividend will be paid to the members on or after June 15, 2013.30 May · Corporate action
Company has fixed Record Date as June 12, 2013 for the purpose of determination of members entitled for dividend.30 May · Dividend
Board of Directors of the Company at its meeting held on May 30, 2013 has declared interim dividend of Rs. 7.50 per equity share of Rs. 5/- each fully paid-up (150%) on 20,47,48,520 equity shares out of the profits for the year ended on March 31, 2013.17 May · Board meeting
To consider amongst other agenda items : (1) To approve audited financial statements for the financial year ended on March 31, 2013; (2) To consider declaration of interim dividend on equity shares for the financial year ended on March 31, 2013.
Apr 2013
18 Apr · Board meeting
To consider a proposal for exploring the possibilities for merger of certain wholly owned subsidiary companies with the Company and to approve the draft Scheme of Amalgamation under section 391-394 of the Companies Act, 1956.
Feb 2013
8 Feb · Results
Consolidated Results for the quarter ended on 31-DEC-2012 as follows: Net Sales of Rs. 156102 lacs for the quarter ending on 31-DEC-2012 against Rs. 151250 lacs and Rs. 135246 lacs for the quarters ending on 30-SEP-2012 and 31-DEC-2011 respectively. Net Profit / (Loss) of Rs. 10291 lacs for the quarter ending on 31-DEC-2012 against Rs. 9514 lacs and Rs. 14921 lacs for the quarters ending on 30-SEP-2012 and 31-DEC-2011 respectively.8 Feb · Results
Standalone Results for the quarter ended on 31-DEC-2012 as follows: Net Sales of Rs. 64775 lacs for the quarter ending on 31-DEC-2012 against Rs. 62323 lacs and Rs. 65286 lacs for the quarters ending on 30-SEP-2012 and 31-DEC-2011 respectively. Net Profit / (Loss) of Rs. 3396 lacs for the quarter ending on 31-DEC-2012 against Rs. 9745 lacs and Rs. 13421 lacs for the quarters ending on 30-SEP-2012 and 31-DEC-2011 respectively.
Jan 2013
16 Jan · Board meeting
To consider amongst others unaudited financial results for the quarter / nine months ended on December 31, 2012.
Nov 2012
7 Nov · Results
Standalone Results for the quarter ended on 30-SEP-2012 as follows: Net Sales of Rs. 62323 lacs for the quarter ending on 30-SEP-2012 against Rs. 60949 lacs and Rs. 60062 lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively. Net Profit / (Loss) of Rs. 9745 lacs for the quarter ending on 30-SEP-2012 against Rs. 13270 lacs and Rs. 23098 lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively.7 Nov · Results
Consolidated Results for the quarter ended on 30-SEP-2012 as follows: Net Sales of Rs. 151250 lacs for the quarter ending on 30-SEP-2012 against Rs. 151610 lacs and Rs. 121964 lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively. Net Profit / (Loss) of Rs. 9514 lacs for the quarter ending on 30-SEP-2012 against Rs. 19479 lacs and Rs. 10268 lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively.
Oct 2012
15 Oct · Board meeting
To consider amongst other unaudited financial results for the quarter/ half-year ended on September 30, 2012.
Aug 2012
24 Aug · Updates
Company has announced the closing of a definitive agreement regarding re-launch of Urokinase, a critical care therapy in North America.7 Aug · Disclosure of Voting Pattern - Clause 35A
6 Aug · Results
Consolidated Results for the quarter ended on 30-JUN-2012 as follows: Net Sales of Rs. 151610 lacs for quarter ending on 30-JUN-2012 against Rs. 117351 lacs for the quarter ending on 30-JUN-2011. Net Profit / (Loss) of Rs. 19479 lacs for the quarter ending on 30-JUN-2012 against Rs. 22982 lacs for the quarter ending on 30-JUN-2011.6 Aug · Results
Standalone Results for the quarter ended on 30-JUN-2012 as follows: Net Sales of Rs. 60949 lacs for quarter ending on 30-JUN-2012 against Rs. 56691 lacs for the quarter ending on 30-JUN-2011. Net Profit / (Loss) of Rs. 13270 lacs for the quarter ending on 30-JUN-2012 against Rs. 15293 lacs for the quarter ending on 30-JUN-2011.
Jul 2012
18 Jul · Board meeting
To consider amongst others unaudited financial results for the quarter ended June 30, 2012.17 Jul · Updates
Vide its letter dated July 17, 2012 that "we have received a letter from USFDA, conveying that our facilities at Moraiya are acceptable. With this, the warning letter issued by them earlier is resolved".
May 2012
17 May · Dividend
Dividend, if declared by the members will be paid to the members on August 11, 2012.11 May · Meeting
Register of Members in respect of Equity Shares of the Company shall remain close from July 30, 2012 to August 06, 2012 (both days inclusive) for the purpose of payment of dividend for the year ended March 31, 2012. Further, the Annual General Meeting of the Company will be held on August 06, 2012.10 May · Dividend
Board of Directors of the Company at its meeting held on May 10, 2012, has recommended a dividend of Rs. 7.50/- [@150%] per equity share on 204,748,520 equity shares of Rs. 5/- each for the financial year ended on March 31, 2012.
Apr 2012
20 Apr · Board meeting
To consider amongst others audited financial results for the year ended on March 31, 2012 and to recommend the dividend on equity shares for the year ended March 31, 2012.
Feb 2012
Jan 2012
23 Jan · Board meeting
To consider amongst others unaudited financial results for the quarter / nine months ended on December 31 ,2011.
Dec 2011
Nov 2011
Oct 2011
17 Oct · Board meeting
To consider amongst other unaudited financial results for the quarter/ half-year ended September 30, 2011.
Jul 2011